Introduction
============

Schizophrenia is a common mental disorder caused by synergic effects of multiple genetic and environmental factors.[@b1-ndt-13-2855] Heritability of up to 80% has been reported for schizophrenia;[@b4-ndt-13-2855] however, the precise etiology of this disease remains inconclusive.[@b2-ndt-13-2855],[@b3-ndt-13-2855] Results of several genome-wide linkage and association studies have indicated genes and chromosomal regions associated with susceptibility to schizophrenia.[@b5-ndt-13-2855],[@b6-ndt-13-2855] Several investigators have suggested that dysregulated dopaminergic neurotransmission has a role in the pathogenesis of schizophrenia.[@b7-ndt-13-2855]--[@b10-ndt-13-2855] Dopamine functions as a neurotransmitter by binding to dopamine receptors on the postsynaptic membrane and autoreceptors on the presynaptic membrane.

Dopamine receptor D3 (*DRD3*) is a candidate gene for evaluating an association between dopaminergic neurotransmission and schizophrenia risk. *DRD3* is located on chromosome 3 in the q13.3 band and has 52% global homology with the D2 receptor band. *DRD3* is primarily expressed in the limbic areas of the human brain[@b11-ndt-13-2855] and contributes emotional, cognitive, and endocrine functions.[@b12-ndt-13-2855] A single-nucleotide polymorphism (SNP) in the first exon of *DRD3* corresponds to a serine-to-glycine substitution at position 9 in the extracellular N-terminal domain of the polypeptide (ie, Ser9Gly \[rs6280\]). Ser9Gly is a functional SNP that yields a protein with altered dopamine-binding affinity.[@b13-ndt-13-2855] The substitution of serine with glycine is thought to yield D3 autoreceptors with a higher affinity for dopamine and more robust intracellular signaling.[@b14-ndt-13-2855] Other authors have associated Ser9Gly with acute pain in sickle cell disease, bipolar disorder, Parkinson's disease, and suicidal behaviors.[@b15-ndt-13-2855]--[@b18-ndt-13-2855]

In recent years, numerous molecular epidemiological studies have addressed the association between Ser9Gly and schizophrenia risk. However, some investigators determined that Ser9Gly was associated with the disease,[@b19-ndt-13-2855],[@b20-ndt-13-2855] whereas others found no association.[@b21-ndt-13-2855]--[@b23-ndt-13-2855] These inconclusive and discordant findings have been attributed to small sample size, inclusion of various genetic backgrounds, and potential confounding bias.[@b24-ndt-13-2855]

Meta-analysis has been applied widely as a statistical method in medical studies, particularly for topics that are studied extensively yet yield controversial results.[@b25-ndt-13-2855] Utsunomiya et al conducted a meta-analysis in 2008 to evaluate the association between Ser9Gly and schizophrenia.[@b26-ndt-13-2855] Their pooled results of 9 case--control studies indicated that Ser9Gly was unlikely to confer susceptibility to schizophrenia in the Japanese population.[@b26-ndt-13-2855] In a second meta-analysis conducted in 2008, results involving 51 case--control studies indicated no association of Ser9Gly with schizophrenia.[@b21-ndt-13-2855] In the years since these meta-analyses were completed, additional molecular epidemiological studies have addressed the roles of Ser9Gly in the occurrence of schizophrenia in various populations. Herein, we describe an updated meta-analysis of studies involving associations between *DRD3* polymorphisms and schizophrenia.

Methods
=======

Identification of relevant studies
----------------------------------

To identify studies eligible for inclusion in this meta-analysis, 3 online electronic English databases (PubMed, Embase, and Web of Science) and 1 online Chinese database (CNKI) were searched. The most recent search was conducted in July 2017. The following key words were used for study identification: *DRD3*, dopamine receptor 3, dopamine D3 receptor, dopamine receptor D3, schizophrenia, polymorphism, and Ser9Gly. Reference lists of the accessed articles and of potentially relevant review articles were screened to identify additional studies.

The following inclusion criteria were applied: 1) case--control design; 2) inclusion of patients with schizophrenia; and 3) statement of allele or genotype frequencies. For studies in which the same or overlapping data were reported by the same authors, the most recent article was selected. Excluded from the meta-analysis were studies 1) without a control population, 2) that duplicated an earlier publication, and 3) that lacked data regarding genotype frequency. Study authors were queried via e-mail for additional study details, such as allele or genotype frequencies or sample characteristics, when these data were not provided in the article.

Data extraction
---------------

Two reviewers independently extracted information from all eligible publications. Disagreements were resolved by discussion until the 2 reviewers reached consensus. The following details of each article were recorded: first author's last name, publication year, sample size, region, and number of genotypes for cases and controls. To detect potentially moderating influences on the effects findings reported in the case--control studies, we also included the following variables: 1) ethnicity of the sample population; 2) source of controls; 3) mean age of the control group; 4) diagnostic criteria; and 5) gender index.

Statistical analysis
--------------------

Stata version 10.0 (Stata Corp., College Station, TX, USA) was applied for statistical analysis. Hardy--Weinberg equilibrium (HWE) was determined for the genotype distribution of controls, and the chi-square goodness-of-fit test was performed to ascertain deviations from HWE. The Thakkinstian method was applied for pooled frequency analysis, as described previously.[@b27-ndt-13-2855] All statistical tests were 2-tailed, and significance was defined as *P*\<0.05.

Odds ratios (ORs) with accompanying 95% confidence intervals (CIs) were calculated to assess the strength of the association of Ser9Gly and schizophrenia. Pooled effect sizes among the included articles were examined with a random effects model, which accounts for heterogeneity among the studies and yields the likely effect size across populations. We did not apply a fixed effects model because we wanted to avoid the assumption that patients were being sampled from a single population. In the fixed effects model, the effect size could be biased by heterogeneity among studies.[@b28-ndt-13-2855]

Three genetic models were applied to determine overall pooled ORs: the allele contrast model, the dominant model, and the recessive model. As previously described, OR~1~ (AA vs aa), OR~2~ (Aa vs aa), and OR~3~ (AA vs Aa) were compared, with A defined as the risk allele.[@b25-ndt-13-2855] The most suitable genetic model was ascertained from these pairwise differences. Specifically, for OR~1~ = OR~3~ ≠1 and OR~2~ =1, the recessive model was selected (OR =1 means *P*\>0.05; OR ≠1 means *P*\<0.05). For OR~1~ = OR~2~ ≠1 and OR~3~ =1, the dominant model was considered. For OR~2~ =1/OR~3~ ≠1 and OR~1~ =1, the complete-overdominant model was presumed. Lastly, for OR~1~\>OR~2~\>1 and OR~1~\>OR~3~\>1 (or OR~1~\<OR~2~\<1 and OR~1~\<OR~3~\<1), the data were evaluated in the context of the codominant model.[@b29-ndt-13-2855]

The degree of heterogeneity between studies was determined by means of the *Q* statistic.[@b30-ndt-13-2855],[@b31-ndt-13-2855] Specifically, *P*\>0.05 by the *Q* test indicated the absence of heterogeneity, and *P*\<0.05 indicated heterogeneity. *I*^2^ was defined as the proportion of observed variance in effect sizes attributable to true differences among studies. Conventional interpretations of *I*^2^ include limits for low (\<25%), moderate (approximately 50%), and high (\>75%) heterogeneity.[@b32-ndt-13-2855] Subgroup analysis was carried out by ethnicity (ie, East Asian, Caucasian, and other populations) and by source of controls (ie, hospital-based and population-based).

Publication bias was evaluated by visual inspection of a funnel plot in which the standard error of log(OR) of each study was plotted against its log(OR). An asymmetric plot implied possible publication bias, and the degree of asymmetry was calculated by means of Egger's test. *P*\<0.05 indicated significant publication bias.[@b33-ndt-13-2855]

Sensitivity analysis was performed to assess the potential influence of a single study on the pooled effect size. Specifically, each study was omitted singly from the meta-analysis, and significant alterations to the pooled effect size were ascertained.

Results
=======

A total of 155 articles were identified by database searches. After removing duplicate or overlapping articles and those that did not fulfill the inclusion criteria, 60 publications were included in the meta-analysis.[@b12-ndt-13-2855],[@b19-ndt-13-2855]--[@b23-ndt-13-2855],[@b26-ndt-13-2855],[@b34-ndt-13-2855]--[@b85-ndt-13-2855] These articles included 73 individual studies that comprised 10,634 patients with schizophrenia (ie, cases) and 11,258 unaffected participants (ie, controls). Patients of diverse races and ethnicities were included (eg, East Asian, Caucasian, Latino, and Indian). The mean age of the controls ranged from 25.0 to 53.0 years. The key characteristics of the studies are summarized in [Table 1](#t1-ndt-13-2855){ref-type="table"}. Genotype and allele frequencies, and details regarding HWE are presented in [Table 2](#t2-ndt-13-2855){ref-type="table"}. For Ser9Gly, the total numbers of Ser/Ser, Ser/Gly, and Gly/Gly genotypes were 5,532, 5,117, and 1,900 for cases and 5,173, 5,066, and 1,022 for controls, respectively. Of the 73 studies, 4 studies deviated significantly from HWE.

Frequency of Ser9Gly in the control population
----------------------------------------------

Pooled frequencies of Ser9Gly stratified by ethnicity were determined for controls. The pooled frequency of Ser9Gly was highest among Latinos (56.8%; 95% CI, 55.9--57.6), followed by African-Americans (56.1%; 95% CI, 55.3--57.0), East Asians (38.2%; 95% CI, 35.0--41.4), Caucasians (29.0%; 95% CI, 27.7--30.4), and Indians (22.0%; 95% CI, 21.7--22.3).

Quantitative synthesis and heterogeneity analysis
-------------------------------------------------

Pooled ORs and corresponding 95% CIs were determined for Ser9Gly in the following genetic models: homozygous codominant, heterozygous codominant, dominant, recessive, and allele contrast ([Table 3](#t3-ndt-13-2855){ref-type="table"} and [Figure 1](#f1-ndt-13-2855){ref-type="fig"}). The dominant model was found to be most appropriate, according to the principles of genetic model selection.[@b29-ndt-13-2855],[@b86-ndt-13-2855] Summary results indicated no association between Ser9Gly and schizophrenia risk. In the dominant model, the pooled OR using a random effects model was 0.950 (95% CI, 0.847--1.064; *P*=0.374). Results of subgroup analysis by ethnicity indicated that the Ser9Gly SNP was not associated with schizophrenia among East Asians, Caucasians, or populations evaluated less frequently in the meta-analysis -- such as Latino, Indian, and African-American patients ([Table 4](#t4-ndt-13-2855){ref-type="table"}). Moreover, no association between Ser9Gly and schizophrenia was observed in subgroup analysis according to the source of controls.

Sensitivity analysis
--------------------

Sensitivity analysis was carried out to ascertain the contribution of each study to the overall result. Corresponding pooled ORs for analyses in which each of the 73 studies was individually removed indicated that no single study produced a significant change in the overall results of the meta-analysis. Hence, these results are stable and reliable.

Publication bias
----------------

A funnel plot was generated to assess potential publication bias ([Figure 2](#f2-ndt-13-2855){ref-type="fig"}), and a small but significant effect of publication bias was detected (*P*~e~=0.040) ([Table 3](#t3-ndt-13-2855){ref-type="table"}).

Discussion
==========

We conducted a meta-analysis of 73 studies (10,634 cases and 11,258 controls) to investigate the potential association of the Ser9Gly SNP in *DRD3* with the occurrence of schizophrenia. Our overall findings suggest that no association exists, and results of subgroup analysis stratified by ethnicity and source of controls further validated the distribution disequilibrium of cases and controls.

Several previous meta-analyses have addressed the putative association between *DRD3* polymorphisms and schizophrenia.[@b21-ndt-13-2855],[@b26-ndt-13-2855],[@b71-ndt-13-2855],[@b80-ndt-13-2855],[@b87-ndt-13-2855] In general, the results of the current meta-analysis were consistent with those published previously, with the exception of 1 meta-analysis in which *DRD3* polymorphisms were found to exert a small but significant effect on schizophrenia susceptibility in Caucasian patients.[@b87-ndt-13-2855] Rather than being superfluous, our meta-analysis has several advantages over previous studies. Most importantly, our analysis involved relevant studies that have been published in the interim since the previous meta-analyses were carried out. We included 73 studies that we believe collectively represent *DRD3* polymorphisms more accurately than did previous meta-analyses. In addition, we performed subgroup analyses stratified by ethnicity and source of controls to assess potential sources of heterogeneity and to test study stability. Therefore, the results of our study provide a more precise, comprehensive assertion that no association exists between Ser9Gly and schizophrenia.

Some authors have described specific ethnic groups for which associations exist between polymorphisms at certain *DRD3* loci and schizophrenia. However, findings of an association of a *DRD3* SNP with schizophrenia in 1 population may not be supported in another population. This phenomenon may result from 2 factors. First, different genetic backgrounds may contribute to divergence. The distribution of *DRD3* allele frequencies varies among Latinos, African-Americans, East Asians, Caucasians, and Indians. Evidently, genetic liability is a high risk factor for schizophrenia.[@b88-ndt-13-2855] Gly9 allele frequencies vary almost as much in the Japanese control populations (22%--34%) as they do in northern and western Caucasian control populations (30%--44%).[@b71-ndt-13-2855] Second, patients from different populations may have disparate lifestyles and may be affected by different environmental factors.[@b89-ndt-13-2855] Epigenetic modifications that contribute to schizophrenia may be a product of transregulatory or environmental risk factors.[@b90-ndt-13-2855]

The relatively small sample sizes of Latino, African-American, Indian, Ashkenazi, and non-Ashkenazi patients limited our ability to isolate stable effects for these subgroups. More studies need to be performed to explore the association between Ser9Gly polymorphism and the risk of schizophrenia in these above populations. Moreover, the lack of an association between Ser9Gly and schizophrenia was upheld when the analysis was stratified by the source of controls. However, control patients in hospital-based studies do not necessarily represent the general population, particularly when the polymorphism being evaluated is related to a disorder that affects hospital-based control patients.[@b91-ndt-13-2855] Thus, the negative results by the source of controls should be interpreted carefully. Because this Gly allele is known to alter dopamine-binding affinity, it can, to some degree, influence the function of dopamine neurotransmitter. Thus, more effort is needed to explore whether it is involved in the risk of schizophrenia.

The present study had several limitations. We observed significant heterogeneity in overall and subgroup analyses. Although we performed subgroup analysis to investigate potential sources of heterogeneity, no single factor completely accounted for this heterogeneity. Therefore, other unidentified aspects might partially contribute to heterogeneity. Second, we detected a slight but significant publication bias in the included studies. This bias can be explained, in part, by our inclusion of only English- and Chinese-language studies. Another main reason is that the negative results are not easier to publish than the positive results. Third, gene--gene interactions and epigenetics were not examined in this meta-analysis, owing to insufficient information in the included studies. By evaluating only 1 SNP in *DRD3*, we may have limited our analysis to a polymorphism that plays a minute role in the overall genetic influences of schizophrenia. This disorder is thought to arise from the mutual influence of multiple genes.

In summary, we found no evidence of an association between the Ser9Gly SNP in *DRD3* and risk of schizophrenia. Studies involving larger sample sizes will be necessary to confirm the results of this meta-analysis -- especially for certain ethnic subpopulations -- and to address the epigenetic mechanisms and environmental influences that contribute to schizophrenia risk.
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###### 

Baseline characteristics of qualified studies in this meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                  Year   Location                       Ethnicity          Controls source    Mean age of control group   Diagnostic criteria   Gender index (case)   Gender index (control)
  ------------------------------------------- ------ ------------------------------ ------------------ ------------------ --------------------------- --------------------- --------------------- ------------------------
  Crocq et al[@b19-ndt-13-2855]               1992   France                         Caucasian          Hospital-based     33.9                        DSM-III-R             0.38                  --

  Crocq et al[@b19-ndt-13-2855]               1992   UK                             Caucasian          Population-based   45.9                        DSM-III-R             0.58                  0.74

  Yang et al[@b61-ndt-13-2855]                1993   China                          East Asians        Population-based   25.05                       RDC                   0.49                  0.56

  Nanko et al[@b64-ndt-13-2855]               1993   Japan                          East Asians        Population-based   27.8                        DSM-III-R             0.82                  0.91

  Jönsson et al[@b67-ndt-13-2855]             1993   Sweden                         Caucasian          Population-based   39                          DSM-III-R             0.46                  0.61

  Nöthen et al[@b72-ndt-13-2855]              1993   Germany                        Caucasian          Population-based   --                          --                    --                    --

  Nöthen et al[@b73-ndt-13-2855]              1993   Germany                        Caucasian          Population-based   28.2                        DSM-III-R             0.5                   0.88

  Laurent et al[@b45-ndt-13-2855]             1994   France                         Caucasian          Population-based   48                          DSM-III-R             0.38                  0.72

  Saha et al[@b53-ndt-13-2855]                1994   Singapore                      East Asians        Population-based   38                          ICD-9                 --                    --

  Mant et al[@b65-ndt-13-2855]                1994   UK                             Caucasian          Population-based   46.6                        DSM-III-R             0.74                  0.8

  Kennedy et al[@b66-ndt-13-2855]             1995   North America                  Caucasian          Hospital-based     --                          DSM-III-R             --                    --

  Kennedy et al[@b66-ndt-13-2855]             1995   Italy                          Caucasian          Hospital-based     --                          DSM-III-R             --                    --

  Inada et al[@b81-ndt-13-2855]               1995   Japan                          East Asians        Population-based   54                          --                    1.09                  1

  Durany et al[@b38-ndt-13-2855]              1996   Spain                          Caucasian          Population-based   53                          ICD-10                1.38                  1.44

  Gaitonde et al[@b41-ndt-13-2855]            1996   UK                             Caucasian          Hospital-based     41.7                        ND                    0.83                  0.93

  Ohara et al[@b50-ndt-13-2855]               1996   Japan                          East Asians        Population-based   34.4                        DSM-IV                --                    1.37

  Rietschel et al[@b51-ndt-13-2855]           1996   Germany                        Caucasian          Population-based   30.2                        DSM-III-R             0.66                  0.96

  Shaikh et al[@b54-ndt-13-2855]              1996   UK                             Caucasian          Hospital-based     --                          DSM-III-R             --                    --

  Tanaka et al[@b59-ndt-13-2855]              1996   Japan                          East Asians        Population-based   42.7                        DSM-III-R             0.92                  0.41

  Nimgaonkar et al[@b20-ndt-13-2855]          1996   USA                            African-American   Hospital-based     --                          DSM-III-R             1.24                  1.33

  Nimgaonkar et al[@b20-ndt-13-2855]          1996   USA                            Caucasian          Hospital-based     --                          DSM-III-R             0.67                  1.1

  Chen et al[@b22-ndt-13-2855]                1997   China                          East Asians        Hospital-based     45                          DSM-III-R             0.86                  1.13

  Ebstein et al[@b39-ndt-13-2855]             1997   Italy                          Caucasian          Population-based   36.5                        DSM-III-R             0.31                  1.03

  Ebstein et al[@b39-ndt-13-2855]             1997   Israel                         Ashkenazi          Population-based   32.9                        DSM-III-R             --                    0.94

  Ebstein et al[@b39-ndt-13-2855]             1997   Israel                         Non-Ashkenazi      Population-based   32.9                        DSM-III-R             --                    0.94

  Maziade et al[@b48-ndt-13-2855]             1997   Canada                         Caucasian          Population-based   --                          DSM-III-R             0.46                  --

  Hawi et al[@b42-ndt-13-2855]                1998   Ireland                        Caucasian          Population-based   --                          DSM-III-R             0.47                  0.79

  Krebs et al[@b92-ndt-13-2855]               1998   France                         Caucasian          Population-based   35.47                       DSM-III-R             0.62                  1

  Spurlock et al[@b56-ndt-13-2855]            1998   Ireland                        Caucasian          Population-based   --                          DSM-III-R             --                    --

  Spurlock et al[@b56-ndt-13-2855]            1998   Northern\                      Caucasian          Population-based   --                          DSM-III-R             --                    --
                                                     Sweden                                                                                                                                       

  Spurlock et al[@b56-ndt-13-2855]            1998   Portugal                       Caucasian          Population-based   --                          DSM-III-R             --                    --

  Spurlock et al[@b56-ndt-13-2855]            1998   Wales                          Caucasian          Population-based   --                          DSM-III-R             --                    --

  Spurlock et al[@b56-ndt-13-2855]            1998   Austria                        Caucasian          Population-based   --                          DSM-III-R             --                    --

  Spurlock et al[@b56-ndt-13-2855]            1998   France                         Caucasian          Population-based   --                          DSM-III-R             --                    --

  Ishiguro et al[@b43-ndt-13-2855]            2000   Japan                          East Asians        Population-based   47.2                        DSM-III-R or ICD-10   0.74                  1.07

  Ishiguro et al[@b43-ndt-13-2855]            2000   Japan                          East Asians        Population-based   48.5                        DSM-III-R or ICD-11   0.9                   0.81

  Joober et al[@b44-ndt-13-2855]              2000   Canada                         Caucasian          Hospital-based     --                          DSM-IV                --                    --

  Meszaros et al[@b49-ndt-13-2855]            2000   Austria                        Caucasian          Population-based   --                          DSM-III-R             --                    --

  Sivagnanasundaram et al[@b55-ndt-13-2855]   2000   UK                             Caucasian          Population-based   --                          DSM-III-R             --                    --

  Hauser et al[@b77-ndt-13-2855]              2000   Poland                         Caucasian          Population-based   28.76                       DSM-IV                --                    --

  Cordeiro et al[@b37-ndt-13-2855]            2001   Brazil                         Latinos            Population-based   --                          ICD-10                --                    --

  Løvlie et al[@b47-ndt-13-2855]              2001   India                          Indians            Population-based   43                          DSM-IV                --                    0.83

  Rybakowski et al[@b52-ndt-13-2855]          2001   Poland                         Caucasian          Population-based   27                          DSM-IV, ICD-10        0.61                  1.13

  Anney et al[@b35-ndt-13-2855]               2002   UK and Ireland                 Caucasian          Population-based   43                          DSM-IV                0.28                  0.28

  Ventriglia et al[@b60-ndt-13-2855]          2002   Italy                          Caucasian          Population-based   --                          DSM-IV                --                    --

  Morimoto et al[@b62-ndt-13-2855]            2002   Japan                          East Asians        Population-based   --                          ICD-10                1.14                  --

  Zhao et al[@b83-ndt-13-2855]                2002   China                          East Asians        Population-based   55.9                        DSM-III-R             0.83                  1.4

  Tang et al[@b84-ndt-13-2855]                2002   China                          East Asians        Population-based   33                          CCMD-II-R             0.76                  1.06

  Jönsson et al[@b71-ndt-13-2855]             2003   Sweden                         Caucasian          Population-based   --                          DSM-III-R             --                    --

  Iwata et al[@b76-ndt-13-2855]               2003   Japan                          East Asians        Population-based   --                          DSM-IV                --                    --

  Baritaki et al[@b36-ndt-13-2855]            2004   Greece                         Caucasian          Population-based   45.1                        DSM-IV                0.7                   0.63

  Jönsson et al[@b63-ndt-13-2855]             2004   Germany                        Caucasian          Population-based   30.2                        DSM-IV                0.85                  0.25

  A et al[@b82-ndt-13-2855]                   2004   China                          East Asians        Population-based   --                          --                    0.63                  --

  Staddon et al[@b57-ndt-13-2855]             2005   Northern Spain                 Basque             Population-based   --                          DSM-IV                0.54                  1

  Yang[@b93-ndt-13-2855]                      2005   China                          East Asians        Population-based   35.04                       DSM-IV                1.12                  1.09

  Liang[@b94-ndt-13-2855]                     2005   China                          East Asians        Population-based   25                          DSM-IV, CCMD-3        0.98                  0.98

  Talkowski et al[@b58-ndt-13-2855]           2006   USA                            Caucasian          Population-based   --                          DSM-IV                --                    --

  Yi et al[@b85-ndt-13-2855]                  2006   China                          East Asians        Population-based   35                          DSM-IV                1.12                  1.13

  Ma et al[@b21-ndt-13-2855]                  2008   China                          East Asians        Hospital-based     35.02                       DSM-IV                0.62                  0.81

  Lorenzo et al[@b46-ndt-13-2855]             2007   Spain                          Caucasian          Population-based   --                          DSM-IV                --                    --

  Chang et al[@b68-ndt-13-2855]               2007   China                          East Asians        Population-based   --                          DSM-IV                --                    --

  Güzey et al[@b34-ndt-13-2855]               2007   Italy                          Caucasian          Population-based   --                          DSM-IV                0.2                   0.17

  Fathalli et al[@b40-ndt-13-2855]            2008   Canada, Tunisia, and Hungary   Caucasian          Hospital-based     --                          DSM-III-R or DSM-IV   0.37                  0.85

  Utsunomiya et al[@b26-ndt-13-2855]          2008   Japan                          East Asians        Population-based   55                          DSM-IV                0.92                  0.92

  Krelling et al[@b78-ndt-13-2855]            2008   Brazil                         Latinos            Population-based   40.27                       --                    --                    --

  Barlas et al[@b23-ndt-13-2855]              2009   Turkey                         Caucasian          Population-based   31.7                        DSM-IV                0.21                  0.23

  Zai et al[@b69-ndt-13-2855]                 2010   Europe                         Caucasian          Population-based   --                          DSM-IV                0.57                  0.42

  Sáiz et al[@b75-ndt-13-2855]                2010   Asturia, Northern Spain        Caucasian          Population-based   40.6                        DSM-IV                0.66                  0.95

  Nunokawa et al[@b80-ndt-13-2855]            2010   Japan                          East Asians        Population-based   38.1                        DSM-IV                0.9                   0.92

  Zhang et al[@b70-ndt-13-2855]               2011   China                          East Asians        Population-based   28.13                       DSM-IV                --                    --

  Tee et al[@b74-ndt-13-2855]                 2011   Malaysia                       East Asians        Population-based   38.4                        --                    0.91                  0.83

  Zheng et al[@b79-ndt-13-2855]               2012   China                          East Asians        Population-based   33.1                        DSM-IV                0.69                  0.72

  Yang et al[@b12-ndt-13-2855]                2016   China                          East Asians        Population-based   42                          DSM-IV                --                    --
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Gender index = (female/male). En dashes indicate data not available.

**Abbreviations:** DSM, *Diagnostic and Statistical Manual of Mental Disorders*; RDC, Research Diagnostic Criteria; ICD, International Classification of Diseases; ND, not determined; CCMD, Chinese Classification of Mental Disorders.

###### 

Distribution of genotype and allele frequencies of the *DRD3* Ser9Gly polymorphism

  References                                  Genotype distribution   *P*~HWE~   Allele frequency                                            
  ------------------------------------------- ----------------------- ---------- ------------------ ----- ----- ---- -------- ---- ---- ---- ----
  Crocq et al[@b19-ndt-13-2855]               37                      26         10                 134   128   24   0.3930   68   32   69   31
  Crocq et al[@b19-ndt-13-2855]               37                      18         13                 170   153   41   0.4616   67   33   68   32
  Yang et al[@b61-ndt-13-2855]                54                      45         8                  56    95    24   0.1630   65   35   59   41
  Nanko et al[@b64-ndt-13-2855]               48                      35         8                  50    40    10   0.6300   72   28   70   30
  Jönsson et al[@b67-ndt-13-2855]             34                      36         6                  63    83    37   0.3154   60   40   55   45
  Nöthen et al[@b72-ndt-13-2855]              31                      22         7                  26    41    4    0.0193   68   32   65   35
  Nöthen et al[@b73-ndt-13-2855]              20                      26         14                 25    34    9    0.6289   68   32   62   38
  Laurent et al[@b45-ndt-13-2855]             35                      33         8                  43    47    10   0.5832   70   30   67   33
  Saha et al[@b53-ndt-13-2855]                62                      66         9                  34    25    4    0.8341   66   34   74   26
  Mant et al[@b65-ndt-13-2855]                33                      23         10                 62    41    6    0.8178   77   23   76   24
  Kennedy et al[@b66-ndt-13-2855]             37                      62         18                 12    14    1    0.2059   61   39   70   30
  Kennedy et al[@b66-ndt-13-2855]             42                      43         12                 73    84    15   0.1807   63   37   67   33
  Inada et al[@b81-ndt-13-2855]               66                      40         7                  34    33    10   0.6569   67   33   66   34
  Durany et al[@b38-ndt-13-2855]              53                      43         11                 92    119   24   0.1064   64   36   64   36
  Gaitonde et al[@b41-ndt-13-2855]            34                      45         5                  56    51    15   0.5255   75   25   67   33
  Ohara et al[@b50-ndt-13-2855]               1                       152        0                  59    58    15   0.8961   77   23   67   33
  Rietschel et al[@b51-ndt-13-2855]           61                      71         14                 42    43    4    0.0865   65   35   71   29
  Shaikh et al[@b54-ndt-13-2855]              33                      56         20                 20    27    5    0.3386   65   35   64   36
  Tanaka et al[@b59-ndt-13-2855]              54                      38         8                  37    40    9    0.707    69   31   66   34
  Nimgaonkar et al[@b20-ndt-13-2855]          30                      22         13                 51    66    15   0.3559   67   33   64   36
  Nimgaonkar et al[@b20-ndt-13-2855]          33                      26         6                  5     13    4    0.3874   54   46   52   48
  Chen et al[@b22-ndt-13-2855]                89                      77         12                 38    35    6    0.5939   78   22   70   30
  Ebstein et al[@b39-ndt-13-2855]             37                      31         12                 49    58    13   0.4951   66   34   65   35
  Ebstein et al[@b39-ndt-13-2855]             24                      15         2                  3     118   0    --       75   25   76   24
  Ebstein et al[@b39-ndt-13-2855]             20                      16         10                 49    42    9    1        66   34   70   30
  Maziade et al[@b48-ndt-13-2855]             41                      27         2                  54    34    6    0.8354   69   31   76   24
  Hawi et al[@b42-ndt-13-2855]                83                      87         28                 59    57    9    0.3379   70   30   69   31
  Krebs et al[@b92-ndt-13-2855]               36                      42         11                 57    69    7    0.0163   66   34   56   44
  Spurlock et al[@b56-ndt-13-2855]            15                      16         5                  25    23    8    0.4763   36   64   83   17
  Spurlock et al[@b56-ndt-13-2855]            25                      29         13                 28    49    8    0.042    64   36   62   38
  Spurlock et al[@b56-ndt-13-2855]            28                      40         8                  27    34    10   0.8928   59   41   62   38
  Spurlock et al[@b56-ndt-13-2855]            14                      15         2                  6     22    5    0.0546   63   37   51   49
  Spurlock et al[@b56-ndt-13-2855]            38                      21         12                 13    16    2    0.3137   69   31   68   32
  Spurlock et al[@b56-ndt-13-2855]            17                      11         2                  23    28    6    0.554    68   32   65   35
  Ishiguro et al[@b43-ndt-13-2855]            84                      61         8                  10    17    4    0.4375   75   25   60   40
  Ishiguro et al[@b43-ndt-13-2855]            61                      31         7                  67    77    12   0.1118   72   28   69   31
  Joober et al[@b44-ndt-13-2855]              44                      50         12                 119   127   26   0.3435   75   25   67   33
  Meszaros et al[@b49-ndt-13-2855]            45                      35         15                 52    43    5    0.2991   73   27   74   26
  Sivagnanasundaram et al[@b55-ndt-13-2855]   29                      40         4                  59    67    12   0.2476   60   40   67   33
  Hauser et al[@b77-ndt-13-2855]              62                      58         9                  50    40    8    1        71   29   71   29
  Cordeiro et al[@b37-ndt-13-2855]            56                      57         28                 19    25    4    0.2847   70   30   66   34
  Løvlie et al[@b47-ndt-13-2855]              16                      29         11                 291   242   51   0.9456   70   30   71   29
  Rybakowski et al[@b52-ndt-13-2855]          54                      55         10                 48    35    7    0.8604   72   28   73   27
  Anney et al[@b35-ndt-13-2855]               152                     178        30                 38    46    13   0.8753   67   33   63   37
  Ventriglia et al[@b60-ndt-13-2855]          43                      51         20                 88    81    19   0.9546   59   41   69   31
  Morimoto et al[@b62-ndt-13-2855]            23                      21         4                  34    26    4    0.7411   65   35   73   27
  Zhao et al[@b83-ndt-13-2855]                109                     109        18                 27    22    4    0.8681   68   32   72   28
  Tang et al[@b84-ndt-13-2855]                273                     210        45                 138   119   28   0.7518   67   33   69   31
  Jönsson et al[@b71-ndt-13-2855]             72                      70         14                 30    30    3    0.1859   63   37   71   29
  Iwata et al[@b76-ndt-13-2855]               73                      64         9                  27    30    8    0.9401   71   29   65   35
  Baritaki et al[@b36-ndt-13-2855]            51                      46         17                 70    66    27   0.098    66   34   63   37
  Jönsson et al[@b63-ndt-13-2855]             326                     255        68                 50    37    7    0.9657   70   30   73   23
  A et al[@b82-ndt-13-2855]                   43                      29         8                  27    21    7    0.3735   71   29   68   32
  Staddon et al[@b57-ndt-13-2855]             59                      40         10                 278   267   51   0.2413   72   28   69   31
  Yang[@b93-ndt-13-2855]                      35                      28         7                  377   341   50   0.019    70   30   71   29
  Liang[@b94-ndt-13-2855]                     65                      30         6                  213   193   36   0.3993   69   31   70   30
  Talkowski et al[@b58-ndt-13-2855]           173                     136        12                 28    27    5    0.6699   70   30   69   31
  Yi et al[@b85-ndt-13-2855]                  35                      28         7                  14    30    16   0.9931   55   45   48   52
  Ma et al[@b21-ndt-13-2855]                  145                     157        7                  47    34    9    0.4449   72   28   71   29
  Lorenzo et al[@b46-ndt-13-2855]             78                      82         18                 66    78    13   0.1281   67   34   67   33
  Chang et al[@b68-ndt-13-2855]               120                     105        31                 115   75    8    0.3241   69   32   77   23
  Güzey et al[@b34-ndt-13-2855]               30                      29         4                  164   188   43   0.3158   62   38   65   35
  Fathalli et al[@b40-ndt-13-2855]            158                     199        51                 39    45    16   0.619    71   29   62   39
  Utsunomiya et al[@b26-ndt-13-2855]          120                     97         29                 26    15    7    0.0729   72   28   70   30
  Krelling et al[@b78-ndt-13-2855]            22                      56         25                 65    39    7    0.7251   71   30   76   24
  Barlas et al[@b23-ndt-13-2855]              47                      37         8                  15    26    20   0.2682   49   52   46   54
  Zai et al[@b69-ndt-13-2855]                 66                      82         15                 177   162   24   0.1038   69   31   71   29
  Sáiz et al[@b75-ndt-13-2855]                103                     123        39                 306   243   46   0.815    71   29   72   28
  Nunokawa et al[@b80-ndt-13-2855]            301                     239        54                 28    19    1    0.2734   76   24   78   22
  Zhang et al[@b70-ndt-13-2855]               345                     274        66                 52    42    11   0.5655   79   21   70   31
  Tee et al[@b74-ndt-13-2855]                 120                     107        34                 153   145   17   0.0195   69   31   72   28
  Zheng et al[@b79-ndt-13-2855]               133                     121        26                 141   89    11   0.5175   72   28   77   23
  Yang et al[@b12-ndt-13-2855]                459                     343        78                 50    37    7    0.9657   70   30   73   27

**Note:** *P*~HWE~ represents the *P*-value of Hardy--Weinberg equilibrium test in the genotype distribution of controls.

###### 

Summarized ORs with 95% CIs for the association of *DRD3* Ser9Gly polymorphism with schizophrenia

  Polymorphism   Genetic model             n    Statistical model   OR      95% CI         *P*~z~   *I*^2^ (%)   *P*~h~     *P*~e~
  -------------- ------------------------- ---- ------------------- ------- -------------- -------- ------------ ---------- --------
  Ser9Gly        Allele contrast           73   Random              0.995   0.925--1.069   0.883    28.6         0.014      0.825
                 Homozygous codominant     73   Random              0.914   0.759--1.102   0.346    62.3         \<0.0001   0.113
                 Heterozygous codominant   73   Random              0.838   0.716--0.981   0.028    47.1         \<0.0001   0.421
                 Dominant                  73   Random              0.950   0.847--1.064   0.374    68.5         \<0.0001   0.040
                 Recessive                 73   Random              1.139   0.965--1.345   0.125    57.0         \<0.0001   0.183

**Notes:** n, number of studies; *P*~z~, *P*-value for association test; *P*~h~, *P*-value for heterogeneity test; *P*~e~, *P*-value for publication bias test.

**Abbreviations:** OR, odds ratio; CI, confidence interval.

###### 

Stratified analysis of the association of *DRD3* polymorphisms with schizophrenia under dominant model

  Subgroup analysis    Ser9Gly                                         
  -------------------- --------- ------- -------------- ------- ------ ----------
  Overall              73        0.950   0.847--1.064   0.374   68.5   \<0.0001
  Ethnicity                                                            
   East Asians         25        0.915   0.751--1.114   0.377   72.8   \<0.0001
   Caucasians          41        0.981   0.880--1.094   0.733   36.2   0.012
   Others              7         0.862   0.368--2.017   0.732   92.2   \<0.0001
  Source of controls                                                   
   Hospital-based      11        1.022   0.861--1.214   0.803   4.6    0.399
   Population-based    62        0.938   0.847--1.064   0.334   72.0   \<0.0001

**Notes:** n, number of studies; *P*~z~, *P*-value for association test; *P*~h~, *P*-value for heterogeneity test. Others included the ethnicities with the rare studies, such as Latino, Indian, and African-American.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
